Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unam pharmaceutical (m) sdn bhd - calcium lactate pentahydrate; calcium pantothenate; cholecalciferol; cyanocobalamin; ferrous fumarate; folic acid; niacinamide; potassium iodide; pyridoxine hydrochloride; retinyl acetate; riboflavin; sodium ascorbate; cupric sulfate anhydrous; thiamine mononitrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

market australia inc - calcium lactate pentahydrate, quantity: 220.35 mg/g (equivalent: calcium, qty 28.87 mg/g); calcium carbonate, quantity: 107.85 mg/g (equivalent: calcium, qty 41.52 mg/g); magnesium oxide, quantity: 27.87 mg/g (equivalent: magnesium, qty 16.47 mg/g); potassium citrate, quantity: 12.19 mg/g (equivalent: potassium, qty 4.34 mg/g); calcium sulfate dihydrate, quantity: 9.57 mg/g (equivalent: calcium, qty 2.125 mg/g); ascorbic acid, quantity: 5.12 mg/g; magnesium carbonate hydrate, quantity: 3.21 mg/g (equivalent - powder, oral - excipient ingredients: fructose; citric acid; potassium bicarbonate; orange; malic acid; glucose monohydrate; silicon dioxide; sucralose; stearic acid; pectin; maltodextrin; modified food starch; medium chain triglycerides; butylated hydroxyanisole; butylated hydroxytoluene; flavour - decrease/reduce/relieve symptoms of soft tissue trauma ; aids/assists healthy bone development/growth/building ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; helps enhance/improve/promote blood circulation to the peripheral areas of the body (legs, hands and feet) ; decrease/reduce/relieve muscle cramps ; aid/assist/helps in the management of muscle sprain/strain ; decrease/reduce/relieve muscle pain/ache/soreness ; helps decrease/reduce/relieve symptoms of medically diagnosed fibromyalgia/fibrositis ; helps decrease/reduce/relieve symptoms of mild medically diagnosed tenosynovitis ; relieve irritability ; decrease/reduce/relieve symptoms of stress ; decrease/reduce/relieve symptoms of mild anxiety ; decrease/reduce/relieve mild migraine symptoms ; helps decrease/reduce/relieve symptoms of mild tension headache ;

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

endeavour ch pty ltd - calcium gluconate monohydrate,calcium lactate pentahydrate,colecalciferol,dibasic magnesium citrate tetrahydrate,magnesium gluconate,zinc citrate trihydrate -

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate tablets contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a c

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unk

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

lupin limited - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are un

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

eci pharmaceuticals, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [ see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calciu

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

avkare, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate, usp is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). - patients with hypercalcemia. patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1) ] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects